Fulcrum Therapeutics (NASDAQ:FULC) Issues Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) issued its earnings results on Friday. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10), FiscalAI reports.

Fulcrum Therapeutics Trading Down 3.8%

NASDAQ FULC opened at $3.58 on Friday. The company has a fifty day simple moving average of $3.99 and a 200 day simple moving average of $6.93. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74. The company has a market cap of $238.54 million, a P/E ratio of -3.11 and a beta of 3.01.

Analyst Ratings Changes

Several brokerages have recently commented on FULC. Jefferies Financial Group set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, June 2nd. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a research note on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Friday, July 17th. HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. Finally, Citigroup lowered Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $8.20.

Insider Activity

In related news, Director Alan Ezekowitz sold 18,000 shares of the company’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the sale, the director owned 10,927 shares in the company, valued at $39,883.55. This represents a 62.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.30% of the stock is owned by corporate insiders.

Institutional Trading of Fulcrum Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FULC. Quarry LP bought a new position in shares of Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Meeder Asset Management Inc. bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $39,000. Russell Investments Group Ltd. raised its position in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after buying an additional 9,092 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Fulcrum Therapeutics in the 4th quarter valued at $75,000. Finally, Evergreen Capital Management LLC purchased a new position in Fulcrum Therapeutics during the 2nd quarter worth $114,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.